Published in Oncologist on August 11, 2011
Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ (2014) 7.21
Vitamin D for health: a global perspective. Mayo Clin Proc (2013) 2.41
Genetic Variations in the Vitamin D Receptor Predict Type 2 Diabetes and Myocardial Infarction in a Community-Based Population: The Tromsø Study. PLoS One (2015) 1.39
Cellular and molecular effects of vitamin D on carcinogenesis. Arch Biochem Biophys (2011) 1.28
Polymorphisms related to the serum 25-hydroxyvitamin D level and risk of myocardial infarction, diabetes, cancer and mortality. The Tromsø Study. PLoS One (2012) 1.23
Plants vs. cancer: a review on natural phytochemicals in preventing and treating cancers and their druggability. Anticancer Agents Med Chem (2012) 1.14
Vitamin D receptor gene polymorphisms and prognosis of breast cancer among African-American and Hispanic women. PLoS One (2013) 0.98
Vitamin D Receptor Gene Expression and Function in a South African Population: Ethnicity, Vitamin D and FokI. PLoS One (2013) 0.93
Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study. BMC Cancer (2014) 0.86
Lifestyle Factors in Cancer Survivorship: Where We Are and Where We Are Headed. J Pers Med (2015) 0.86
Vitamin d: are we ready to supplement for breast cancer prevention and treatment? ISRN Oncol (2013) 0.83
25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance). J Natl Cancer Inst (2014) 0.81
Vitamin D receptor FokI gene polymorphisms may be associated with colorectal cancer among African American and Hispanic participants. Cancer (2014) 0.80
The effect of pre-diagnostic vitamin D supplementation on cancer survival in women: a cohort study within the UK Clinical Practice Research Datalink. BMC Cancer (2015) 0.78
Breast cancer survival among young women: a review of the role of modifiable lifestyle factors. Cancer Causes Control (2016) 0.77
Immune regulatory activity of vitamin d3 in head and neck cancer. Cancers (Basel) (2013) 0.77
Calcium and vitamin D intakes in children: a randomized controlled trial. BMC Pediatr (2013) 0.76
The association between Vitamin D and health outcomes in women: A review on the related evidence. J Res Med Sci (2016) 0.76
Validation of a vitamin D replacement strategy in vitamin D-insufficient patients with lymphoma or chronic lymphocytic leukemia. Blood Cancer J (2017) 0.75
Association of Low Levels of Vitamin D with Chronic Stable Angina: A Prospective Case-Control Study. N Am J Med Sci (2016) 0.75
Vitamin D deficiency. N Engl J Med (2007) 59.34
Vitamin D deficiency and risk of cardiovascular disease. Circulation (2008) 13.39
Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (2010) 8.89
High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc (2006) 8.78
Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst (2007) 4.89
Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer (2004) 4.10
Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer. J Clin Oncol (2008) 3.17
Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr (2008) 3.09
An international comparison of serum 25-hydroxyvitamin D measurements. Osteoporos Int (1999) 3.07
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol (2007) 3.05
High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol (2009) 2.97
Serum 25-hydroxyvitamin D3 levels are associated with breslow thickness at presentation and survival from melanoma. J Clin Oncol (2009) 2.85
Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. J Clin Oncol (2007) 2.52
Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol (2009) 2.49
Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway). Cancer Causes Control (2004) 2.04
Vitamin D and cancer. J Steroid Biochem Mol Biol (2006) 1.72
Vitamin D receptor polymorphisms and diseases. Clin Chim Acta (2006) 1.65
Association between serum 25(OH)D and death from prostate cancer. Br J Cancer (2009) 1.55
Prognostic significance of vitamin D receptor and retinoid X receptor expression in renal cell carcinoma. J Urol (2007) 1.46
Circulating 25-hydroxyvitamin D, VDR polymorphisms, and survival in advanced non-small-cell lung cancer. J Clin Oncol (2008) 1.42
Consequences of vitamin D receptor gene polymorphisms for growth inhibition of cultured human peripheral blood mononuclear cells by 1, 25-dihydroxyvitamin D3. Clin Endocrinol (Oxf) (2000) 1.30
Vitamin D receptor: key roles in bone mineral pathophysiology, molecular mechanism of action, and novel nutritional ligands. J Bone Miner Res (2007) 1.22
Immunohistochemical identification of the PTHR1 parathyroid hormone receptor in normal and neoplastic human tissues. Eur J Endocrinol (2010) 1.16
Association of breast cancer progression with a vitamin D receptor gene polymorphism. South-East Sweden Breast Cancer Group. Cancer Res (1999) 1.15
A novel polymorphism in the 1A promoter region of the vitamin D receptor is associated with altered susceptibilty and prognosis in malignant melanoma. Br J Cancer (2004) 1.13
Polymorphisms of vitamin D receptor and survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev (2006) 1.10
Distinct conformations of vitamin D receptor/retinoid X receptor-alpha heterodimers are specified by dinucleotide differences in the vitamin D-responsive elements of the osteocalcin and osteopontin genes. Mol Endocrinol (1996) 1.09
Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression. Cancer Epidemiol Biomarkers Prev (2003) 1.01
Vitamin D in cancer patients: above all, do no harm. J Clin Oncol (2009) 1.00
Vitamin D receptor expression as a predictive marker of biological behavior in human colorectal cancer. Clin Cancer Res (1998) 0.99
Parathyroid hormone-related protein regulates cell survival pathways via integrin alpha6beta4-mediated activation of phosphatidylinositol 3-kinase/Akt signaling. Mol Cancer Res (2009) 0.94
Vitamin D receptor gene polymorphisms are associated with increased risk and progression of renal cell carcinoma in a Japanese population. Int J Urol (2007) 0.92
Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer. Clin Cancer Res (2008) 0.91
Overexpression of vitamin D receptor indicates a good prognosis for cholangiocarcinoma: implications for therapeutics. Cancer (2007) 0.91
1,25 Dihydroxyvitamin D(3) receptor expression in superficial transitional cell carcinoma of the bladder: a possible prognostic factor? Eur Urol (2005) 0.90
Vitamin D receptor polymorphisms and prognosis of patients with epithelial ovarian cancer. Br J Cancer (2009) 0.90
Vitamin D receptor gene polymorphisms and disease free survival after radical prostatectomy. Prostate (2004) 0.83
Clinical importance of vitamin D receptor gene polymorphism in invasive ductal carcinoma. Int Surg (2010) 0.78
Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med (2007) 6.58
Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol (2005) 6.38
A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med (2007) 4.59
Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med (2012) 2.82
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood (2008) 2.68
Maternal complications and procedures in pregnancy and at birth and wheezing phenotypes in children. Am J Respir Crit Care Med (2006) 2.56
Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med (2014) 2.33
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol (2010) 2.27
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. J Clin Oncol (2007) 2.14
Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res (2006) 1.92
Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int (2004) 1.78
Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood (2011) 1.76
Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study. Am J Gastroenterol (2008) 1.69
Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer (2010) 1.56
Digestive endoscopy is not a major risk factor for transmitting hepatitis C virus. Ann Intern Med (2005) 1.55
Effectiveness of a lifestyle intervention on metabolic syndrome. A randomized controlled trial. J Gen Intern Med (2007) 1.53
Developing clinical recommendations for breast, colorectal, and lung cancer adjuvant treatments using the GRADE system: a study from the Programma Ricerca e Innovazione Emilia Romagna Oncology Research Group. J Clin Oncol (2008) 1.46
Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol (2011) 1.42
Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol (2006) 1.41
Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer (2005) 1.39
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood (2004) 1.37
Validity of hospital morbidity records for amyotrophic lateral sclerosis. A population-based study. J Clin Epidemiol (2002) 1.36
Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial. Scand J Gastroenterol (2008) 1.33
A high positive predictive value algorithm using hospital administrative data identified incident cancer cases. J Clin Epidemiol (2007) 1.30
Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases. J Cell Physiol (2011) 1.27
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica (2013) 1.26
Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol (2007) 1.25
Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. J Clin Oncol (2008) 1.25
Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European group for blood and marrow transplantation experience. Biol Blood Marrow Transplant (2009) 1.19
Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. Clin Cancer Res (2008) 1.17
The role of lung metastasis resection in improving outcome of colorectal cancer patients: results from a large retrospective study. Oncologist (2012) 1.16
Diagnostic accuracy and complication rate of CT-guided fine needle aspiration biopsy of lung lesions: a study based on the experience of the cytopathologist. Acta Radiol (2010) 1.15
Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. Haematologica (2009) 1.15
Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients. Eur J Cardiothorac Surg (2008) 1.14
Changes in prevalence of asthma and allergies among children and adolescents in Italy: 1994-2002. Pediatrics (2006) 1.11
Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer. Eur Urol (2010) 1.11
Risk factors for early and late mortality in hospitalized older patients: the continuing importance of functional status. J Gerontol A Biol Sci Med Sci (2003) 1.09
Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease. J Urol (2007) 1.08
Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology). J Neurooncol (2013) 1.07
Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer. Clin Genitourin Cancer (2013) 1.07
Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. BJU Int (2012) 1.07
Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Endocr Relat Cancer (2007) 1.07
Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification. Histopathology (2009) 1.06
Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. Clin Cancer Res (2009) 1.05
The metabolic syndrome and high C-reactive protein: prevalence and differences by sex in a southern-European population-based cohort. Diabetes Metab Res Rev (2005) 1.03
Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. Haematologica (2012) 1.03
Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J (2004) 1.03
Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer. Clin Cancer Res (2002) 1.03
Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica (2011) 1.02
Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. J Clin Oncol (2010) 1.02
Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years. Eur J Endocrinol (2007) 1.01
Human ASH1 expression in prostate cancer with neuroendocrine differentiation. Mod Pathol (2008) 1.00
International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). J Natl Cancer Inst Monogr (2011) 1.00
Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer. Endocr Relat Cancer (2006) 0.99
Gene expression profiling in breast cancer: a clinical perspective. Breast (2013) 0.99
Side-to-side stapled anastomosis strongly reduces anastomotic leak rates in Crohn's disease surgery. Dis Colon Rectum (2005) 0.98
Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica (2002) 0.98
Gemcitabine and protracted 5-fluorouracil infusion as third-line chemotherapy in refractory colorectal cancer patients. Anticancer Res (2008) 0.98
Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr Relat Cancer (2008) 0.97
The reticulin algorithm for adrenocortical tumor diagnosis: a multicentric validation study on 245 unpublished cases. Am J Surg Pathol (2013) 0.96
Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urol Oncol (2002) 0.96
Safety and efficacy of endoscopic retrograde cholangiopancreatography in patients with post-liver transplant biliary complications: results of a cohort study with long-term follow-up. Gut Liver (2011) 0.96
Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network. BMC Cancer (2009) 0.96
Risk factors for disease progression in advanced jejunoileal neuroendocrine tumors. Neuroendocrinology (2011) 0.96
Patients with type 2 diabetes had higher rates of hospitalization than the general population. J Clin Epidemiol (2004) 0.95
Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. Haematologica (2013) 0.94
Seizure control following radiotherapy in patients with diffuse gliomas: a retrospective study. Neuro Oncol (2013) 0.94
Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res (2008) 0.94
Respiratory symptoms in children living near busy roads and their relationship to vehicular traffic: results of an Italian multicenter study (SIDRIA 2). Environ Health (2009) 0.93
Bone morphogenetic proteins and bone defects: a systematic review. Spine (Phila Pa 1976) (2007) 0.93
Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach. Crit Rev Oncol Hematol (2008) 0.93
Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. J Clin Oncol (2002) 0.92
Exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 0.92
Guidelines for preoperative assessment: impact on clinical practice and costs. Int J Qual Health Care (2005) 0.92
Prevalence of undiagnosed metabolic syndrome in a population of adult asymptomatic subjects. Diabetes Res Clin Pract (2006) 0.92
Muscle tenderness in different headache types and its relation to anxiety and depression. Pain (2004) 0.90
Accessibility as a major determinant of radiotherapy underutilization: a population based study. Health Policy (2006) 0.90
Osteonecrosis of the jaw after zoledronic acid and denosumab treatment. J Clin Oncol (2011) 0.90
Implementing guidelines for venous thromboembolism prophylaxis in a large Italian teaching hospital: lights and shadows. Haematologica (2005) 0.90
Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: results from a prospective, multicenter study. Oncology (2007) 0.90